SIR-The synonymous mutation C957T in the human D2 dopamine receptor (DRD2) has been shown to reduce mRNA stability and synthesis of the receptor in vitro
1
. We studied whether this polymorphism affects in vivo DRD2 binding in 45 healthy subjects using [
11 C]raclopride and positron emission tomography (PET). Subjects carrying the 957T allele had markedly lower striatal D2 receptor availability. This in vivo neurobiological correlate in the brain makes the C957T an interesting candidate for genetic predisposition studies in neuropsychiatric disorders.
Dopamine receptor D2 (DRD2) has been suggested to be involved in the biology of several neuropsychiatric disorders, 2 and is an important target for drug treatment, for example, in schizophrenia. Previous PET studies have revealed a high interindividual variation in striatal DRD2 density in vivo, 3,4 part of which is explained by genetic factors. 4 Recently reported synonymous C957T polymorphism of DRD2 dramatically decreases DRD2 mRNA stability and receptor synthesis, which makes it a potent DRD2 expression-regulating factor in vitro.
We tested whether the DRD2 C957T polymorphism and a related modulating polymorphism, G1101A, 1 affect DRD2 density in vivo in man. DRD2 availability (binding potential, BP) was measured by using [ 11 C]raclopride and PET 5 in a previous sample of healthy volunteers.
4
The frequencies of C and T alleles of C957T polymorphism were comparable to frequencies in European-American population described by Duan et al.
1 1101A allele of G1101A polymorphism did not occur in any subject in this study and thus only C957T polymorphism is included in our analysis.
A linear regression analysis indicated that the C957T genotype had a highly significant effect on DRD2 BP (P ¼ 0.004, R 2 ¼ 0.179) with highest BP in C/C, intermediate in C/T and lowest in T/T genotype ( Figure 1 ). The effect of the C957T genotype on DRD2 BP was identical after adjusting for age. The C957T genotype explained 18% of the variance in the striatal DRD2 BP, whereas aging and C957T together explained 35.3% of the BP variance. We have previously reported that the A1 allele of the TaqIA RFLP associates with low striatal DRD2 BP.
4 Therefore, we entered also the TaqIA RFLP genotype in the model that now explained 40.1% of BP variance (R 2 ¼ 0.401). The effect of C957T and aging remained significant in this model (P ¼ 0.028 and P ¼ 0.004, respectively), whereas the Taq1A effect on DRD2 BP variability was significant only at a trend level (P ¼ 0.080).
In accordance with the previous in vitro study, 1 we found that the C957T polymorphism associates with low DRD2 receptor binding potential in vivo. The C957T genotype explained about 18% of the striatal DRD2 BP variance, which is somewhat higher than that reported previously for the A1 allele of TaqIA RFLP (12%; 4 ). The C957T and TaqIA polymorphisms have been reported to be in linkage disequilibrium.
1
The effect of TaqIA RFLP on DRD2 BP was weaker than that of C957T, but still almost statistically significant in the regression analysis. We have previously observed that the A1 allele of the TaqIA RFLP is associated with decreased inhibition of striatal dopamine synthesis in vivo ([ 18 F]DOPA uptake), whereas the C957T polymorphism had a weaker and nonsignificant effect on this index of dopamine synthesis. 6 In fact, the TaqIA RFLP was recently reported to be a potentially functional nonsynonymous polymorphism of a novel kinase-like gene adjacent to DRDR gene. 7 It is possible that TaqIA RFLP has a C957T-independent effect in DRD2 BP and dopamine synthesis, although the effects of C957T polymorphism and Taq1A RFLP on these measures in our studies differ only quantitatively and not qualitatively.
The C957T polymorphism has a neurobiological correlate and endophenotype in DRD2 binding in human brain in vivo. This makes the C957T polymorphism 2 We hypothesized that part of the heterogeneity of disease course in schizophrenia is related to different contributing genetic factors. The neuregulin 1 gene (NRG1), assumed to be involved in glutamate neurotransmission and neurodevelopment, was recently reported to be associated with schizophrenia in several, but not all populations. [3] [4] [5] [6] [7] [8] [9] We have investigated the association of NRG1 with schizophrenia in patients with and without the deficit syndrome.
In order to enrich the sample for patients with the deficit syndrome, 282 schizophrenia patients were mainly recruited from psychiatric hospitals. Patients had at least three Dutch-born Caucasian grandparents. DSM-IV diagnosis of schizophrenia, excluding schizoaffective disorder, was made using the Comprehensive Assessment of Symptoms and History 10 and information from medical records. The Schedule for the Deficit Syndrome (SDS) 11 was completed for 260 patients (92.2%), 130 of whom met deficit criteria. In 29 patients with severe negative symptoms, it could not be ruled out that these symptoms were secondary to factors such as substance abuse. Following the SDS, they were classified as nondeficit schizophrenia. The Medical Ethical Committee of the UMC Utrecht approved the study and all patients gave written informed consent. The control panel (n ¼ 585) consisted of 472 DNA samples from random Dutch individuals, obtained from the Immunogenetics and Transplantation Immunology Section of the Department of Immunohematology and Blood Transfusion, LUMC, Leiden and 113 healthy controls from our department. Under optimal conditions, these samples have approximately 90% power to detect a locus with a relative risk of 1.5, and still 75% to detect a locus with an RR of 1.25.
All five single-nucleotide polymorphisms (SNPs) from the previously reported at-risk haplotype 5 were first screened in DNA pools from an unselected subset of patients (n ¼ 208) and independent controls (n ¼ 179), using the SNaPshot technique (Applied Biosystems, Foster City, CA, USA). SNP8NRG221533 was genotyped individually on a 7900HT TaqMan system (Applied Biosystems). Microsatellites 478B14-642 and 478B14-848 5 ) were analyzed on an ABI 3700 sequencer (Applied Biosystems) and genotyped by two independent raters. Genepop 12 software was used to verify Hardy-Weinberg equilibrium (HWE). Haplotypes, linkage disequilibrium (LD) and likelihood ratios were calculated using UNPHASED software.
13 Alleles and haplotypes with frequencies o1% were combined. Global P-values were calculated using nÀ1 degrees of freedom (n ¼ number of alleles or haplotypes). No correction of P-values for testing several markers and haplotypes was applied, because the markers were in LD and tests are therefore not independent. SNP8NRG221533, which was the most strongly associated single marker in previous studies, showed a significantly higher frequency of the T allele in the schizophrenia pool than in controls (Po0.01). This marker was then genotyped individually in the extended sample, as was microsatellite 478B14-848, which is part of the reported at-risk haplotype. 4 Before testing for association, we calculated LD between the markers, and found it to be low (D 0 ¼ 0.20), which is in agreement with a recent study.
8 Therefore, we genotyped microsatellite 478B14-642, instead of the even more distant third microsatellite from the reported atrisk haplotype. This marker is located much closer to the SNP, and was recently found to be in a different LD block than 478B14-848. 8 Indeed, in our sample, 478B14-642 was in considerable LD with SNP8NR G221533 (D 0 ¼ 0.60), but not with 478B14-848. All three markers were in HWE.
Interestingly, SNP8NRG221533 was associated with nondeficit schizophrenia (P ¼ 0.004), but not with deficit schizophrenia (P ¼ 0.542). Likewise, haplotypes of SNP8NRG221533 and 478B14-642 were
